Rios MB - Search Results

1

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Kantarjian HM, et al. Among authors: rios mb. Blood. 1993 Mar 1;81(5):1146-51. Blood. 1993. PMID: 8382970 Free article. Clinical Trial.

2

Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.

Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Kantarjian HM, et al. Among authors: rios mb. Blood. 1992 Feb 15;79(4):876-81. Blood. 1992. PMID: 1737098 Free article.

3

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. O'Brien S, et al. Among authors: rios mb. Blood. 1995 Nov 1;86(9):3322-6. Blood. 1995. PMID: 7579434 Free article.

4

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.

Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Suki S, et al. Among authors: rios mb. Cancer. 1993 Oct 1;72(7):2155-60. doi: 10.1002/1097-0142(19931001)72:7<2155::aid-cncr2820720715>3.0.co;2-v. Cancer. 1993. PMID: 8374873 Clinical Trial.

5

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.

Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Estey E, et al. Among authors: rios mb. Leuk Lymphoma. 1993 Mar;9(4-5):343-50. doi: 10.3109/10428199309148532. Leuk Lymphoma. 1993. PMID: 8394169 Clinical Trial.

6

Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.

Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Estey EH, et al. Among authors: rios mb. Leuk Lymphoma. 1993;10 Suppl:115-21. doi: 10.3109/10428199309149123. Leuk Lymphoma. 1993. PMID: 8481661 No abstract available.

7

Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.

Kantarjian HM, Beran M, O'Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M, et al. Kantarjian HM, et al. Among authors: rios mb. Leukemia. 1996 Mar;10(3):396-401. Leukemia. 1996. PMID: 8642853 Clinical Trial.

8

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

Koller CA, Kantarjian HM, Thomas D, O'Brien S, Rios MB, Kornblau S, Murphy S, Keating M. Koller CA, et al. Among authors: rios mb. Leukemia. 1997 Dec;11(12):2039-44. doi: 10.1038/sj.leu.2400861. Leukemia. 1997. PMID: 9447817

9

Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.

Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Beran M, et al. Among authors: rios mb. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2377-84. Clin Cancer Res. 1997. PMID: 9815637 Clinical Trial.

10

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. O'Brien S, et al. Among authors: rios mb. Blood. 1999 Jun 15;93(12):4149-53. Blood. 1999. PMID: 10361112 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters